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Abstract
Background: Visfatin is a multifaceted adipokine whose circulating levels are enhanced in different metabolic
diseases. Extracellular visfatin can exert various deleterious effects on vascular cells, including inflammation and
proliferation. Limited evidence exists, however, on the capacity of human vascular cells to synthesize and release
visfatin by themselves, under basal or pro-inflammatory conditions.
Methods and Results: Intracellular visfatin was detected by Western blot in non-stimulated human umbilical vein
endothelial cells (HUVEC). However, exposing HUVEC for 18 h to a series of pro-inflammatory stimulus, such as
interleukin (IL)-1β (1 to 10 ng/mL), tumor necrosis factor-α (1 to 10 ng/mL) or angiotensin II (10 pmol/L to 1 μmol/L)
markedly enhanced intracellular visfatin content. Using IL-1β (10 ng/mL; 18 h), it was determined that the increase in
intracellular visfatin, which was paralleled by enhanced visfatin mRNA levels, relied on a signalling mechanism
involving both nuclear factor-κB and poly (ADP ribose) polymerase-1 activation. Moreover, IL-1β modified the sub-
cellular localization of visfatin; while in non-stimulated HUVEC immunoreactive visfatin predominantly showed an
intra-nuclear granular pattern, in IL-1β-inflamed cells an extra-nuclear filamentous staining, co-localising with F-actin
fibers and suggesting a secretory pattern, was mainly found. Indeed, IL-1β promoted visfatin secretion, as
determined by both ELISA and immunocytochemistry.
Conclusions: Human endothelial cells synthesize and release visfatin, particularly in response to inflammation. We
suggest that the inflamed endothelium can be a source of visfatin, which arises as a local inflammatory mediator and
a potential therapeutic target to interfere with vascular inflammation.
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Introduction
Visfatin is a multifaceted molecule initially proposed to be
mainly released by visceral fat [1], structurally identical to pre-
B-cell colony-enhancing factor (PBEF) [2], and exhibiting
nicotinamide phosphoribosyltransferase (Nampt) enzymatic
activity [3,4]. For this reason, different reports have referred to
this adipocytokine as PBEF/Nampt/visfatin [4,5]. Enhanced
circulating levels of visfatin have been reported in patients
affected by metabolic disorders, such as diabetes mellitus,
obesity or the metabolic syndrome [6,7], which might be related
to the development of cardiovascular complications linked to
these diseases. Supporting this, plasma visfatin concentrations
have been positively associated with vascular damage and
endothelial dysfunction in type 2 diabetes mellitus [8] and
chronic kidney disease [9]. Furthermore, enhanced visfatin
content has been detected in human unstable atherosclerotic
plaques [10], while it has been proposed as a novel marker of
carotid atherosclerosis in type 2 diabetes [11].
There is growing evidence that extracellular visfatin can
directly promote endothelial dysfunction by exerting a series of
deleterious actions on the vascular wall [7,12]. In human
vascular smooth muscle, visfatin can directly promote
inflammation through the activation of the extracellular-signal
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regulated kinase (ERK) 1/2 - nuclear factor (NF)-κB - inducible
nitric oxide synthase (iNOS) axis [5]. Moreover, visfatin derived
from perivascular adipose tissue stimulates vascular smooth
muscle cells proliferation [13]. In human endothelial cells,
visfatin promotes NF-κB activation, leading to the expression of
vascular adhesion molecules, matrix metalloproteinases
activation and the release of cytokines and chemokines,
including interleukin (IL)-6 or monocyte chemotactic protein-1
[14–16]. Moreover, while a vasculoprotective role of visfatin
has been claimed through the release of endothelial nitric oxide
[17], other studies have shown the capacity of visfatin to impair
endothelium-dependent relaxation in isolated mesenteric
microvessels from both animals and humans [18,19]. Some of
the deleterious vascular effects elicited by visfatin seem to rely
on Nampt enzymatic activity, which transforms nicotinamide
into nicotinamide monucleotide [5,13,19].
Despite the interest in understanding the vascular impact of
exogenous visfatin, little is known about the capacity of
vascular cells themselves to synthesize and release visfatin
that might act as an autocrine or paracrine regulator within the
vasculature. In the present work, we have explored such
capacity using human endothelial cell cultures, with special
attention to the role played by inflammation, considered as a
hallmark of atherothrombotic diseases.
Materials and Methods
Ethics Statement
The investigation conforms to the principles outlined in the
Declaration of Helsinki and to Spanish legal dispositions.
Experiments with human umbilical vein endothelial cells were
reviewed and approved by the ethics committee of Universidad
Autónoma de Madrid and Hospital Universitario de Getafe. A
written informed consent was obtained from every umbilical
cord donor.
Materials
Culture plasticware was from TPP (Tragadingen,
Switzerland). M199 medium and fetal calf serum (FCS) was
from Biological Industries (Beit-Haemek, Israel). IL-1β with an
endotoxin level below 0.1 ng per μg, was from Peprotech
(London, UK). Endothelial cell growth supplement (ECGS),
pyrrolidine dithiocarbamate (PDTC), PJ34 and, unless
otherwise stated, all other reagents were from Sigma Chemical
Co. (St. Louis, MO, USA).
Cell culture
Human umbilical vein endothelial cells (HUVEC) were
enzymatically isolated, as previously described [20]. For
experiments, cells at passages 1-4 were incubated with
different compounds in M199 medium supplemented with 10%
FCS, ECGS and antibiotics for 18 h. The investigation
conforms to the principles outlined in the Declaration of
Helsinki. Experiments with human cells were reviewed and
approved by the ethics committee of Universidad Autónoma of
Madrid and Hospital Universitario of Getafe, respectively, and
written informed consent was obtained from all donors.
Western blotting
Proteins (20 μg) were separated by SDS-PAGE, transferred
to nitrocellulose membranes (Whatman, Kent, UK) and probed
with a primary polyclonal antibody against either PBEF/Nampt/
visfatin (dilution 1/500; Affinity Bioreagents, Golden, CO, USA)
or PARP-1 (dilution 1/1000, Trevigen, Gaithersburg, MD, USA),
followed by an appropriate horseradish peroxidase-conjugated
secondary antibody (dilution 1/10,000; Millipore, Bedford, MA,
USA), as previously described [5]. Immunoreactive bands were
detected by enhanced chemiluminescence (GE Healthcare,
Uppsala, Sweden) and quantified using NIH Image software.
The membranes were probed with an anti α-tubulin primary
antibody (dilution 1/10,000) to ensure equal loading.
Indirect immunofluorescence
Visfatin was localized in HUVEC by indirect
immunofluorescence using a primary polyclonal antibody
against visfatin (dilution 1/50, Affinity Bioreagents, Golden, CO,
USA), followed by a FITC-conjugated secondary antibody
(dilution 1/200). To visualize F-actin filaments, cells were co-
stained with phalloidine-TRITC (dilution 1/200). Cell nuclei
were counterstained with 1 μmol/L 4'-6-diamidino-2-
phenylindole (DAPI; Molecular Probes-Invitrogen Corporation,
Carlsbad, CA, USA) and observed under an Eclipse TE300
epifluorescence microscope (Nikon, Tokyo, Japan) and a
spectral confocal microscope (LEICA TCSSP5-AOBS, Leica
microsystems, Heidelberg, GMBH, Germany). Confocal images
were analysed with LAS AF software, version 1.5.1 Build 869
(LEICA).
Reverse-transcriptase polymerase chain reaction (RT-
PCR)
Total RNA was extracted using a commercial kit (RNeasy,
Qiagen; Hilden, Germany), quantified by measuring
absorbance at 260 nm and aliquots of 1μg RNA were reverse-
transcribed using a commercial kit (iScript CDNA Synthesis kit,
Bio-Rad, Hercules, CA, USA). The resulting cDNA was
amplified using human visfatin primers
(5’GGAGGGTGACGGGGTGAAGG3’,
5’GTCGGTGGCCAGGAGGATGTT3’) and human 18S as an
internal control (5’GGAAGGGCACCACCAGGAGT3’,
5’TGCAGCCCCGGACATCTAAG3’). The reaction was
conducted in an ATC 401 thermocycler (Nyx Technik, San
Diego, CA, USA), with an initial denaturation step at 95°C for 3
min, followed by 30 cycles each consisting of incubation at
94°C for 30s, 59°C for 40s, and 72°C for 30s. Aliquots of the
resulting PCR products were loaded on 1% agarose gels
containing ethidium bromide. The resulting bands were
visualized under ultraviolet light in a transiluminator coupled to
a camera (Chemidoc™ XRS System, Bio-Rad, Hercules,
California, USA), and quantified using NIH Image software
(Image J version 1.4).
Detection and quantification of visfatin secretion
Visfatin secretion by endothelial cells was visualized by
adapting a previously described immunohistochemistry
protocol [21] to HUVEC seeded on Immobilon-P membranes
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(Millipore, Bedford, MS, USA) coated with type I collagen. With
this procedure the cell secretion products become firmly bound
to the membrane. At the end of the treatments, the membranes
were collected, fixed with Bouin’s fixative and blocked.
Endogenous peroxidase was inhibited with 1% hydrogen
peroxide and the membranes were probed with an antibody
against human visfatin (1/50), followed by HRP-conjugated
secondary antibody and addition of a diaminobencidine-based
substrate for peroxidase (Vector Laboratories, Burlingame, CA,
USA). Air-dried membranes mounted on coverslips were
visualized on a brightfield microscope Eclipse TE300 (Nikon,
Tokio, Japan). Images were captured with a SPOT 1.3.0
camera coupled to the microscope with Adobe Photoshop 6.0.
software. In parallel experiments, visfatin was quantified in cell
supernatants with an extracellular visfatin detection kit
(Adipogen, Incheon, South Korea) following the manufacturer’s
guidelines. The absorbance at 450 nm was measured in an
ELISA plate reader ELx 800 (BIO-TEK Instruments, Winooski,
VT, USA).
Statistical analysis
Results are expressed as mean ± SEM of at least three
independent experiments. Statistical analysis was performed
using ANOVA followed by Fisher’s LSD test for curves or
Student’s t-test for data points, with the level of significance
chosen at P<0.05.
Results
Inflammation promotes visfatin synthesis in HUVEC
Using Western blot techniques, immunoreactive visfatin was
detected in HUVEC cultures under non-inflammatory conditions
(Figure 1A). However, after challenging the cells with a well-
known pro-inflammatory stimulus, such as the cytokine IL-1β (1
to 10 ng/mL; 18 h), a concentration-dependent increase in the
cellular levels of visfatin was observed, with a threshold at 2,5
ng/mL (Figure 1A). At the 10 ng/mL concentration, IL-1β
already significantly increased visfatin levels at 12 h, with a
maximum reached at 18 h, then followed by a slow and
progressive decay at 24 and 48 h (Figure 1B). Moreover, the
stimulation of HUVEC with two other vascular pro-inflammatory
stimuli such as tumor necrosis factor (TNF)-α (1 to 10 ng/mL;
18 h) or angiotensin II (10 pmol/L to 100 nmol/L; 18h) also
resulted in a concentration-dependent enhancement of cellular
visfatin content at thresholds of 2.5 ng/mL and 1 nmol/l,
respectively (Figures 1C and 1D).
Furthermore, IL-1β (10 ng/mL; 18 h), selected as a model of
pro-inflammatory stimulus, increased HUVEC visfatin mRNA
levels, suggesting a de novo synthesis of visfatin triggered by
the cytokine (Figure 2A).
Nuclear factor-κB and poly (ADP ribose) polymerase-1
mediate visfatin synthesis by HUVEC in response to
inflammation
To gain insight into the intracellular pathways mediating the
induction of visfatin by inflammation in HUVEC, the implication
of nuclear factor (NF)-κB and poly (ADP ribose) polymerase
(PARP)-1 activation, as relevant molecules involved in
inflammatory responses, was next explored. Figures 2B and
2C illustrate the stimulation of NF-κB DNA binding activity and
PARP-1 activity by IL-1β (10 ng/mL; 18 h). respectively.
Indeed, a sequential NF-κB - PARP-1 activation pathway was
indicated by the fact that the NF-κB inhibitor PDTC (10 µmol/L)
abrogated PARP-1 activation by IL-1β (Figure 2C). Both NF-κB
and PARP-1 were necessary for visfatin induction in HUVEC,
as their respective inhibitors PDTC and PJ34 (100 µmol/L)
prevented the increase in visfatin levels triggered by IL-1β
(Figure 2D).
Inflammation modifies the sub-cellular distribution of
visfatin in HUVEC
Using immunofluorescence techniques, we observed that,
under non-inflammatory conditions, visfatin predominantly
exhibited a granular pattern localized within the cell nucleus
(Figures 3A, left panel, and Figure 3B). However, 18 h after
exposing HUVEC to IL-1β (10 ng/mL) a marked positive extra-
nuclear filamentous staining for visfatin was also observed
(Figure 3A right panel and Figure 3C). To analyse whether
these filaments did co-localize with some cytoskeleton element,
we used fluorescence-labelled phalloidin to detect F-actin.
Figures 3A and 3C show that IL-1β promoted the co-
localization of visfatin with F-actine fibers, particularly in the
cytoplasm and at the cell surface (Figure 3A right pannel and
3C), suggesting a secretory pattern.
Figure 1.  Inflammation enhances intracellular visfatin
levels in HUVEC.  (A) Concentration-dependent effect of IL-1β
(1 to 10 ng/mL; 18 h) on cellular visfatin content determined by
Western blotting. (B) Time course of visfatin induction by IL-1β
(10 ng/mL) over 48 h. Visfatin content was also determined in
HUVEC challenged for 18 h with either (C) TNF-α (1 to 10
ng/mL) or (D) Ang II (10 pmol/L to 1 µmol/L). Data are the
mean±SEM of five independent experiments. *P<0.05 vs non-
stimulated cells. Representative gels are shown on the top.
doi: 10.1371/journal.pone.0078283.g001
Visfatin Release by Inflamed Human Endothelium
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e78283
Inflammation promotes visfatin secretion by HUVEC
There has been controversy about the capacity of visfatin to
be secreted to the extracellular space, as this protein lacks a
signal peptide [22,23]. To explore the capacity of HUVEC to
secrete visfatin, we first used an immunocytochemical
approach to detect visfatin in the extracellular space [21]. As
shown in Figure 4A, IL-1β promoted visfatin release, visualized
as a stained halo surrounding each secreting cell. This
secretion halo could not be observed in HUVEC treated with
the PARP-1 inhibitor PJ34 (100 µmol/L; Figure 4A). As a
second approach, visfatin was quantified using ELISA, and
significantly higher levels were found in the supernatant of
HUVEC challenged with IL-1β as compared with non-
stimulated ones (Figure 4B).
Discussion
A few years ago, Fukuhara et al [1] first identified visfatin as
a new adipocytokine identical to PBEF, a 52 kDa cytokine
acting on early B-lineage precursor cells [2], and to the enzyme
Nampt [3,4], which plays an essential role in the biosynthesis of
NAD+ by converting nicotinamide into nicotinamide
Figure 2.  The sequential activation of NF-κB and PARP-1
activation mediates inflammation-evoked visfatin
production.  (A) Relative mRNA expression of visfatin in
HUVEC treated with or without IL-1β (10 ng/mL; 18 h). (B) NF-
κB activation in HUVEC after incubation with IL-1β (10 ng/mL)
for 1 h was determined by EMSA. Data are the mean±SEM of
four independent experiments. *P<0.05 vs basal levels. (C)
Auto-modified immunoreactive PARP-1 in HUVEC stimulated
for 18 with or without IL-1β (10 ng/mL; 18 h), in the absence or
presence of the respective PARP-1 and NF-κB inhibitors PJ34
(10 µmol/L) and PDTC (100 µmol/L). Data are the mean±SEM
of four independent experiments. *P<0.05 vs basal; †P<0.05 vs
IL-1β. (D) Visfatin protein levels in HUVEC treated with IL-1β
(10 µmol/L; 18 h) with or without PJ34 (10 µmol/L) or PDTC
(100 µmol/L). Data are the mean±SEM of four independent
experiments. *P<0.05 vs basal; †P<0.05 vs IL-1β.
Representative gels are shown.
doi: 10.1371/journal.pone.0078283.g002
mononucleotide (NMN), which is then transformed into NAD+
by nicotinamide/nicotinic acid mononucleotide
adenyltransferase (Nmnat) [24]. Despite in the last years
different studies have demonstrated the capacity of exogenous
visfatin to directly induce vascular cell damage [5,13–16,19],
whether vascular cells themselves synthesize and release
visfatin to the extracellular milieu has been only scarcely
addressed.
In the present study, immunoreactive visfatin was detected in
cultured human endothelial cells. Most noticeably, the
intracellular visfatin levels were markedly enhanced in
response to a series of molecules implicated in vascular
inflammation and disease, such as IL-1β, TNF-α or Ang II.
Therefore, one first finding of this study was that inflamed
human endothelial cells over-produce visfatin. This is most
likely explained by a de novo visfatin synthesis, as indicated by
the increase of visfatin mRNA levels in response to a pro-
inflammatory stimulus.
Supporting this observation, Williams et al [25] showed in a
wide microarray study that visfatin was among the factors
whose mRNA was increased upon IL-1β -stimulation in
HUVEC, although the post-transcriptional impact of such
Figure 3.  Inflammation modifies the sub-cellular
distribution pattern of visfatin in HUVEC.  (A) Confocal
maximum projections showing a general view of stained nuclei
(blue), visfatin (green), F-actin (red), and merge (yellow) in
HUVEC cultures. In non-stimulated HUVEC (left), visfatin is
mainly localized within the cell nucleus, while in HUVEC
stimulated with IL-1β (10 ng/mL) for 18 h (right), visfatin can be
markedly found in non-nuclear localizations together with F-
actin. 630x magnification. (B) Magnified view of the visfatin
granular nuclear distribution in non-stimulated HUVEC at 400x
(left) and 1,000x (right) magnification. Nuclei were
counterstained with 4'-6-diamidino-2-phenylindole (DAPI). (C)
Magnified view of the visfatin non-nuclear filamentous
distribution pattern in HUVEC stimulated with IL-1β (10 ng/mL).
1,000x magnification.
doi: 10.1371/journal.pone.0078283.g003
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finding on visfatin protein levels was not explored. Other
reports using different cell types have reported visfatin
production in response to inflammatory conditions such as
labour, acute lung injury, sepsis or rheumatoid arthritis [26–29].
Moreover, here we have gained insight into the signalling
mechanisms mediating visfatin induction by inflamed
endothelial cells by identifying the sequential activation of NF-
κB and PARP-1 as a key event in such process.
A second main finding of the present study was that
inflammation not only increased visfatin synthesis but also
modified the sub-cellular distribution of visfatin while enhancing
the secretion of the adipokine to the extracellular space. In line
with this observation, changes in the sub-cellular visfatin
distribution have been previously reported in non-proliferating
PC-12 cells or confluent Swiss 3T3 fibroblasts when these cell
types are activated by proliferative stimuli [22]. Indeed, two
different forms of Nampt/visfatin, both intracellular and
extracellular, have been identified to date. On one hand, the
intracellular form would play a central role in maintaining the
activity of different NAD-dependent enzymes that are
implicated in the regulation of cell metabolism [4,24]. This form
has been involved as a NAD supplier for a number of NAD-
consuming enzymes acting intra-nuclearly, which are involved
in key enzymatic reactions for cell growth and survival [30,31].
In human vascular smooth muscle cells, the intracellular form
has been identified as a regulator of NAD-dependent protein
deacetylase activity, promoting cell maturation and increasing
Figure 4.  Inflammation promotes visfatin secretion by
HUVEC.  (A) Representative microphotographs of visfatin
release from HUVEC grown on Immobilon-P membranes and
treated with or without IL-1β, (10 ng/mL; 18 h) in the absence
or the presence of the PARP-1 inhibitor PJ34 (10 µmol/L).
Secreted visfatin appears as a diffuse halo of extracellular
positive immunostaining (black arrows). Magnification 400x. (B)
Visfatin content determined by ELISA in cell supernanants
treated with or without IL-1β (10 ng/mL; 18 h). Data are the
mean±SEM for four independent experiments. *P<0.05 vs
basal.
doi: 10.1371/journal.pone.0078283.g004
lifespan [32,33], while improving the functionality and
angiogenic capacity, as well as its replicative lifespan, in
human endothelial cells [34,35]. In this context, the present
study localizes intra-nuclear Nampt/visfatin as the predominant
form in non-inflamed endothelial cells, which most likely reflects
cell maintenance functions.
On the other hand, the extracellular form of Nampt/visfatin is
synthesized and released to the extracellular milieu, where it
could exert a variety of actions in a paracrine or endocrine
manner [4]. Structurally, extracellular visfatin shows a slightly
higher molecular weight than the intracellular isoform and
seems to undergo post-transcriptional modifications [4,24].
Here, we have demonstrated the secretory activity of human
endothelial cells through both the immunolocalization and
quantification of visfatin in the extracellular space, which was
particularly evident under inflammatory conditions. There has
been controversy on the ability of visfatin to be secreted to the
extracellular milieu, since this protein lacks a signal sequence
for secretion [3,22,23]. However, other well-characterised
peptides lacking a signal sequence for secretion, including the
pro-inflammatory cytokine IL-1β itself, are released by a wide
variety of cell types [36,37].
In the last years, a role for visfatin as a possible link between
metabolic disorders and atherothrombotic inflammatory
diseases has been supported [38]. Enhanced circulating
visfatin has been proposed as an atherosclerosis marker
[11,39], while other studies suggest that it rather reflects the
global inflammatory status in patients with cardiovascular and
renal diseases [40]. Not only circulating visfatin, but also
perivascular adipose tissue-derived visfatin has been related to
coronary and aortic atherosclerosis [41]. This observation
highlights that locally produced visfatin may play an important
paracrine role in the development of atherosclerotic lesions. In
this context, activated monocytes/macrophages that closely
interact with vascular cells do release visfatin [42]. Increased
visfatin expression has been described in macrophages of
human unstable carotid and coronary atherosclerotic plaques
[10] suggesting that locally produced visfatin should be
regarded as an inflammatory mediator with a role in plaque
destabilization. In the present study, we have demonstrated
that human endothelial cells, which constitutively express
visfatin, synthesize and release significantly higher amounts of
the adipokine in response to inflammation. Therefore, not only
macrophages and perivascular adipose tissue, but also the
inflamed endothelium itself represents a local source of visfatin
that may promote and amplify vascular damage.
In conclusion, human endothelial cells synthesize and
secrete visfatin, which is particularly reinforced in a pro-
inflammatory environment. Whilst acknowledging the limitations
of an in vitro study, we propose that visfatin released by
endothelial cells may act as a local pro-inflammatory mediator
in the vascular wall with a potential role in atherothrombotic
diseases.
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